Drug recall · September 4, 2024
Cefixime for Oral Suspension USP recall
Why: Subpotent Drug- An out of specification ( OOS ) result observed in assay test during 18-month long term stability study.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Cefixime for Oral Suspension USP, 100 mg/5 mL, 50 mL bottle, Rx only, Manufactured for: Lupin Pharmaceuticals, Inc., Baltimore, Maryland 21202, Manufactured by: Lupin Limited, Mandideep 462 046 INDIA, NDC 68180-405-01
- Lots / codes
Lot #: F201517, Exp 11/30/2024
- Quantity
- 4554 bottles
- Company
- Lupin Pharmaceuticals Inc., Baltimore, MD
- Distribution
- USA nationwide.
- Initiated
- August 21, 2024 · Voluntary: Firm initiated
- Classified
- August 26, 2024
- Reported
- September 4, 2024
- Ended
- April 29, 2025
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Cefixime
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.